Maxim Group Maintains Talphera(TLPH.US) With Buy Rating, Maintains Target Price $3
Bullish Outlook on Talphera's Niyad: Phase 3 Trial Advancements and Market Potential Justify Buy Rating
Talphera Analyst Ratings
A. G. P. Initiates Talphera(TLPH.US) With Buy Rating, Announces Target Price $3.5
H.C. Wainwright Maintains Talphera(TLPH.US) With Buy Rating, Maintains Target Price $6
Buy Rating Affirmed for Talphera Amid Strategic Advancements in NEPHRO CRRT Study
Optimistic Buy Rating for Talphera Despite Phase 3 Trial Enrollment Delay
Talphera Analyst Ratings
Analysts Are Bullish on These Healthcare Stocks: Talphera (TLPH), NexGel Inc (NXGL)
Talphera Analyst Ratings
Talphera Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Talphera, Maintains $6 Price Target
Talphera Analyst Ratings
Talphera's Strategic Rebrand and Niyad's Market Potential Bolster Buy Rating
HC Wainwright & Co. Reiterates Buy on AcelRx Pharmaceuticals, Maintains $5 Price Target
AcelRx Pharmaceuticals Analyst Ratings
Alliance Global Partners Initiates Coverage On AcelRx Pharmaceuticals With Buy Rating, Announces Price Target of $4.25
AcelRx Pharmaceuticals Analyst Ratings
HC Wainwright & Co. Maintains Buy on AcelRx Pharmaceuticals, Lowers Price Target to $5
AcelRx Pharmaceuticals Analyst Ratings